Novo Nordisk has cut its forecast for the fourth time this year, after disappointing sales of its blockbuster drugs Wegovy and Ozempic. It underscores the challenges facing its new chief executive Mike Doustdar. He spoke to Bloomberg's Guy Johnson about the experience so far.

Ford CEO Jim Farley, Oracle Red Bull Racing CEO Talk Carmaker Industry
12:24

Rep. French Hill Talks Fed Subpoenas
09:02

ECB's Kazaks Talks Central Bank Pressure
10:13